Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease

Journal of Rheumatology

Volumn 30, Issue 10, 2003, Pages 2147-2151

  La Montagna, Giovanni ^a   D'Angelo, Salvatore ^b   Valentini, Gabriele ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE

Author keywords

Soluble interleukin 2 receptor joint involvement; Systemic sclerosis; Ykl 40 serum levels

Indexed keywords

C REACTIVE PROTEIN; GLYCOPROTEIN GP 39; INTERLEUKIN 2 RECEPTOR; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SOLUBLE INTERLEUKIN 2 RECEPTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; YKL 40 PROTEIN;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CARTILAGE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBROBLAST; HUMAN; JOINT FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RATING SCALE; SCORING SYSTEM; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTHRITIS; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOPROTEINS; HUMANS; JOINTS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; RECEPTORS, INTERLEUKIN-2; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND FACTOR;

EID: 0141865738     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Clements PJ, Furst DE. Systemic Sclerosis. Baltimore: William and Wilkins; 1996.
2. Blocka KLN, Bassett LW, Furst DE, Clements PJ, Paulus HE. The arthropathy of advanced progressive systemic sclerosis. A radiographic survey. Arthritis Rheum 1981;24:874-84.
3. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;208:25803-10.
4. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001;285:926-31.
5. Johansen JS, Olee T, Price PA, Hashimoto S, Ochs RL, Lotz M. Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 2001;44:826-37.
6. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signaling pathways. Biochem J 2002;365:119-26.
7. Tran A, Benzaken S, Saint-Paul MC, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000;12:989-93.
8. Johansen JS, Christoffersen P, Moller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911-20.
9. Harvey S, Weisman M, O'Dell J, et al. Chondrex: A new marker of joint disease. Clin Chem 1998;3:509-16.
10. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949-55.
11. Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: Correlations between clinical and laboratory parameters. Clin Exp Rheumatol 2001;19:655-60.
12. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Mignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60:619-26.
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
14. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986;13:911-6.
15. Clements PJ. Lachenbruch M, Seibold JR, et al. Inter and intra observer variability of total skin thickness score (modified-Rodnan) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
16. Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
17. Herrick AL, Illingworth K, Blann A, Hay CRM, Hollis S, Jayson MIV. Von Willebrand factor, thrombomodulin, thromboxane, beta thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122-7.
18. Black CM, McWhirter A, Harrison NK, Kirm JME, Laurent CJ. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol 1989;28:98-103.
19. Steen VD, Engel EE, Charley MR, Medsger TA. Soluble serum interleukin-2 receptors in patients with systemic sclerosis. J Rheumatol 1996;23:46-9.
20. La Montagna G, Baruffo A, Tirri R, Buono G, Valentini G. Foot involvement in systemic sclerosis: A longitudinal study of 100 patients. Semin Arthritis Rheum 2002;31:248-55.
21. Rodnan GP. The nature of joint involvement in progressive systemic sclerosis (diffuse scleroderma). Clinical study and pathologic examination of synovium in 29 patients. Ann Intern Med 1962;56:422-38.
22. Volck B, Ostergaard K, Johansen JS, Garbarsch C, Price PA. The distribution of YKL-40 in osteoarthritic and normal human articular cartilage. Scand J Rheumatol 1999;28:171-9.
23. Vos K, Steenbakkers P, Miltenburg AMM, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000;59:544-48.
24. Conrozier Th, Carlier MC, Mathieu P, et al. Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study. Ann Rheum Dis 2000;59:828-31.
25. Johansen JS, Hvorlis J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults, comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996;35:553-9.
26. Cintin C, Johansen JS, Christiansen IJ, Price PA, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999;79:1494-9.
27. Verheijden GFM, Rijnders AWM, Bos E, et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 1997;40:1115-25.
28. Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 2001;20:192-6.
29. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: Relation to disease activity. Rheumatology 1999;38:618-26.
30. Harvey S, Whaley J, Eberhardt K. The relationship between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis. Scand J Rheumatol 2000;29:391-3.
31. Picillo U, Migliaresi S, Vatti M, Marcialis MR, Ferruzzi AM, Tirri G. Demographic differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1993;36:1332-4.